Literature DB >> 26029542

An unusual cause of an anterior mediastinal mass.

I Hassan1, A Goolam-Mahomed1.   

Abstract

Mesothelioma is a rare tumour and its radiological growth pattern varies. We report the case of a biopsy proven Malignant Pleural Mesothelioma (MPM) presenting as an anterior mediastinal mass in a platinum miner. The prognosis for this aggressive tumour remains poor, despite combination treatment modalities.

Entities:  

Keywords:  Anterior mediastinal mass; Biopsy; CT scan pattern; Chest pain; MPM (malignant pleural mesothelioma); Occupational hazard

Year:  2014        PMID: 26029542      PMCID: PMC4061419          DOI: 10.1016/j.rmcr.2013.12.004

Source DB:  PubMed          Journal:  Respir Med Case Rep        ISSN: 2213-0071


Introduction

MPM presenting as a mediastinal mass is rare. Malignant mesothelioma is manifested in four ways; irregular pleural thickening, pleural effusion, lung encasement by tumour rind and parenchymal nodular lesions at the periphery (Table 1) [1]. Asbestos exposure and less commonly simian virus 40 are associated as causes of malignant mesothelioma [2]. MPM presenting as an anterior mediastenal mass is not well described in the literature.
Table 1

Frequency of occurrence, sensitivity and specificities for malignant pleural disease using CT scan.

Sensitivity (%)Specificity (%)Frequency
Pleural rind41100Very common
Nodular thickening5194Common
Parietal thickening3694Common
Mediastinal pleural disease5688Uncommon

Case report

A 56 year old non-smoker male, with a more than 25 year occupational history of platinum mining, presented with unrelenting chest pain that was neither ischaemic nor pleuritic in nature. He had a history of progressive dyspnoea. Physical examination showed clubbing of the digits, an uncommon finding in MPM. The flow volume loop (spirometery) disclosed a mild obstructive pattern. MPM and asbestosis usually demonstrates a restrictive pattern. The clinical significance of this pattern in this patient is uncertain. On bronchoscopy for airway examination the bronchial lavage retrieval yielded a ferruginised asbestos body [Fig. 2.1]. Following a CT Scan of the chest [Figs. 1.1 and 1.2], the diagnosis was established on an ultrasound-guided core biopsy of the mediastinal mass that stained positive for mesothelial markers, including calretinin [Fig. 2.2], AE1/AE3 cytokeratin [Fig. 2.3]and epithelial membrane antigen[Fig. 2.4]. The patient had a high performance status at the time of diagnosis, and was treated with palliative chemotherapy, opioid analgesics and carbamezapine for neuropathic pain, but succumbed a year later to his disease [Fig. 1.3].
Fig. 2.1

Feruginised asbestos body.

Fig. 2.2

Positive calretinin stain high magnification.

Fig. 2.3

Positive AE1/3 cytokeratin stain.

Fig. 2.4

Positive epithelial membrane antigen stain.

Fig. 1.3

Chest X-ray a year later demonstrating extensive bilateral lung involvement suggesting miliary spread.

Discussion

Reported cases of malignant pleural mesothelioma are rare, 3–4/million a year in industrialised countries [2,3]. Only 10% report a history of asbestos exposure, with a latency period of approximately 15 years [4,5,10]. The link between asbestos exposure and MPM was first reported in South Africa in 1960 [3,5]. Asbestos is a common component of insulation, ceiling, roofing vinyls cement and automobile breaking material. Chest pain is an important symptom and is usually neuronal or somatic, due to intercostal nerve and localized invasion respectively. Radiotherapy should not be used to treat nerve root pain as it may cause tissue necrosis and further compression of intercostal nerves [6]. Local invasion to the pericardium and spinalcord may also occur. The common sights of spread are the hilar, mediastinal and supra clavicular lymphnodes. Metastasis to bone may also occur and miliary spread is occasionally apparent [Fig. 1.3] [4]. Asbestos bodies in BAL fluid correlate with occupational exposure [6]. Asbestos bodies are easily identified and quantified by light microscopy; an asbestos body recovery of more than one Ab/ml indicates a high probability of occupational exposure. Asbestos bodies are asbestos fibres that have been coated with an iron rich proteinaceous concretion. Amphibole asbestos forms majority of asbestos bodies and is more persistent in lung tissue than chrysolite. Greater than 8 AB/ml on BAL is strongly correlated with malignant mesothelioma or lung cancer [6]. The notion that some fibres are safer than others should be abandoned, as all asbestos are fibrogenic and carcinogenic [6,7]. CT is the first line and most common imaging modality for the evaluation of mesothelioma [Table 1].MRI and PET scan are useful in delineating the extent of the disease, staging and guiding biopsy sites. The recently described “pointillism” (Speckled hyper intensity on DWI due to tumour deposits) sign on MRI has a high positive predictive value for the diagnosis of MPM [8]. Immunohistochemistry markers are important for determining the tissue of origin in mesothelial cell (calretinin), and its malignant potential (EMA), and AE1/3 cytorkeratin suggests invasion [3,4,9,10]. A specific known marker for MPM has not been recognised; in general Calretinin, keratin 5/6 and podoplanin are considered to be the positive mesothelioma markers. Immunohistostaining helps distinguish mesothelioma from adenocarcinoma; CEA and BerEp4 are the best negative markers for distinguishing between adenocarcinoma and mesothelioma. In challenging situations electron microscopy may be necessary [4,9]. Malignant pleural mesothelioma is a highly aggressive and treatment resistant tumour [11]. Median survival is 9 months from time of diagnosis [2-4]. Molecular targeted therapies may yield promising new treatment options but are still in its infancy and unproven. Further studies looking at surgical debulking procedures, chemotherapy and radiotherapy are needed to improve treatment outcome and survival [12].

Conclusion

The anterior mediastinum is a common location for thymic lesion, germ cell tumours, lymphomas and endocrine tumours in adults. Mesenchymal tumours localised to the anterior mediastinum compartment is rare in adults. Evidence is lacking for any relation between platinum mining and the development of mesothelioma. MPM presenting in this location and in this fashion is atypical. The pleura share an interface with the lung on both the parenchymal and mediastinal sides. MPM can therefore present as a mass with a sharp incomplete border that is frequently tapered on either the parenchymal or mediastinal sides. CT scan has a poor sensitivity and specificity for diagnosing mediastinal side MPM and therefore a certain diagnosis can and must only be made by biopsy.

Conflict of interest

No conflict of interest.
  12 in total

1.  Shattered lives: asbestos-related diseases.

Authors:  Sat Sharma
Journal:  Curr Opin Pulm Med       Date:  2012-07       Impact factor: 3.155

Review 2.  Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.

Authors:  Samuel G Armato; Zacariah E Labby; Johan Coolen; Astero Klabatsa; Malcolm Feigen; Thorsten Persigehl; Ritu R Gill
Journal:  Lung Cancer       Date:  2013-08-15       Impact factor: 5.705

Review 3.  Immunohistochemical diagnosis of epithelioid mesothelioma: an update.

Authors:  Nelson G Ordóñez
Journal:  Arch Pathol Lab Med       Date:  2005-11       Impact factor: 5.534

4.  Localized malignant mesothelioma.

Authors:  Timothy Craig Allen; Philip T Cagle; Andrew M Churg; Thomas V Colby; Allen R Gibbs; Samuel P Hammar; Joseph M Corson; Margaret M Grimes; Nelson G Ordonez; Victor Roggli; William D Travis; Mark R Wick
Journal:  Am J Surg Pathol       Date:  2005-07       Impact factor: 6.394

5.  Pleural mesothelioma: clinical features and therapeutic implications.

Authors:  S S Legha; F M Muggia
Journal:  Ann Intern Med       Date:  1977-11       Impact factor: 25.391

Review 6.  Malignant mesothelioma.

Authors:  Bruce W S Robinson; Arthur W Musk; Richard A Lake
Journal:  Lancet       Date:  2005 Jul 30-Aug 5       Impact factor: 79.321

7.  Complete response and long-term survival in malignant pleural mesothelioma: case report.

Authors:  Silvia Takanen; Blerina Resuli; Vanessa Graziano; Alessandro Parisi; Roberto Lisi; Nicola Raffetto; Vincenzo Tombolini
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

Review 8.  The epidemiology of mesothelioma.

Authors:  Mark Britton
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

Review 9.  Malignant pleural mesothelioma: a comprehensive review.

Authors:  Roohi Ismail-Khan; Lary A Robinson; Charles C Williams; Christopher R Garrett; Gerold Bepler; George R Simon
Journal:  Cancer Control       Date:  2006-10       Impact factor: 3.302

Review 10.  Imaging of pleural masses: which to choose?

Authors:  Aaron S Bruns; John G Mastronarde
Journal:  Respir Med       Date:  2007-12-20       Impact factor: 3.415

View more
  4 in total

1.  Rare presentation of a localised malignant pleural mesothelioma with cranial metastasis.

Authors:  Gulhan Ertan; Abdulkadir Eren; Sila Ulus
Journal:  BMJ Case Rep       Date:  2016-10-04

2.  Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor.

Authors:  Takuya Hino; Takeshi Kamitani; Koji Sagiyama; Yuzo Yamasaki; Isamu Okamoto; Tetsuzo Tagawa; Kayo Ijichi; Hidetaka Yamamoto; Hidetake Yabuuchi; Hiroshi Honda
Journal:  Eur J Radiol Open       Date:  2019-01-31

3.  Mediastinal undifferentiated pleomorphic sarcoma with pleural effusion cytopathologically misdiagnosed as epithelial malignant pleural mesothelioma: An autopsy case report.

Authors:  Kinnosuke Matsumoto; Yukihiro Nakamura; Yuji Inagaki; Yoshihiko Taniguchi; Akihiro Tamiya; Yoshinobu Matsuda; Takahiko Kasai; Shinji Atagi
Journal:  Thorac Cancer       Date:  2021-02-19       Impact factor: 3.500

Review 4.  When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines.

Authors:  Giulio Rossi; Fabio Davoli; Venerino Poletti; Alberto Cavazza; Filippo Lococo
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.